Neurofilament Light Chain as a Biomarker in Multiple Sclerosis

Kristin N Varhaug, Øivind Torkildsen, Kjell-Morten Myhr, Christian A Vedeler, Kristin N Varhaug, Øivind Torkildsen, Kjell-Morten Myhr, Christian A Vedeler

Abstract

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS.

Keywords: axonal damage; biomarker; cerebrospinal Fluid—CSF; multiple scleorsis (MS); neurofilament light (NF-L); serum.

References

    1. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. (1998) 64:402–4. 10.1136/jnnp.64.3.402
    1. Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol. (2004) 204:438–49. 10.1002/path.1650
    1. Chevalier-Larsen E, Holzbaur EL. Axonal transport and neurodegenerative disease. Biochim Biophys Acta. (2006) 1762:1094–108. 10.1016/j.bbadis.2006.04.002
    1. Karlsson JE, Rosengren LE, Haglid KG. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. J Neurochem. (1991) 57:1437–44. 10.1111/j.1471-4159.1991.tb08311.x
    1. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. (1996) 67:2013–8. 10.1046/j.1471-4159.1996.67052013.x
    1. Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, et al. . Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology. (2018) 91:e1338–e47. 10.1212/WNL.0000000000006282
    1. Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. . Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. (2018) 90:e22–30. 10.1212/WNL.0000000000004761
    1. Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. . Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. (2016) 3:623–36. 10.1002/acn3.325
    1. Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. . Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. (2017) 81:857–70. 10.1002/ana.24954
    1. Basal E, Zalewski N, Kryzer TJ, Hinson SR, Guo Y, Dubey D, et al. . Paraneoplastic neuronal intermediate filament autoimmunity. Neurology. (2018) 91:e1677–89. 10.1212/WNL.0000000000006435
    1. Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. (2018) 23:174–7. 10.1111/jns.12279
    1. Piehl F, Kockum I, Khademi M, Blennow K, Lycke J, Zetterberg H, et al. . Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. (2018) 24:1046–54. 10.1177/1352458517715132
    1. Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, et al. . Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. (2011) 76:1206–13. 10.1212/WNL.0b013e31821432ff
    1. Kuhle J, Plattner K, Bestwick JP, Lindberg RL, Ramagopalan SV, Norgren N, et al. . A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler. (2013) 19:1597–603. 10.1177/1352458513482374
    1. Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. (2016) 54:1655–61. 10.1515/cclm-2015-1195
    1. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. . Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. (2010) 28:595–9. 10.1038/nbt.1641
    1. Novakova L, Zetterberg H, Sundstrom P, Axelsson M, Khademi M, Gunnarsson M, et al. . Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. (2017) 89:2230–7. 10.1212/WNL.0000000000004683
    1. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's disease neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease. JAMA Neurol. (2017) 74:557–66. 10.1001/jamaneurol.2016.6117
    1. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. (2019) 25:277–83. 10.1038/s41591-018-0304-3
    1. Modvig S, Degn M, Horwitz H, Cramer SP, Larsson HB, Wanscher B, et al. . Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE. (2013) 8:e77163. 10.1371/journal.pone.0077163
    1. Modvig S, Degn M, Roed H, Sorensen TL, Larsson HB, Langkilde AR, et al. . Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. (2015) 21:1761–70. 10.1177/1352458515574148
    1. Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, et al. . Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler. (2016) 22:590–8. 10.1177/1352458515599074
    1. Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeno JC, Picon C, et al. . Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. (2016) 87:1076–84. 10.1212/WNL.0000000000003085
    1. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, et al. . Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. (2009) 72:1322–9. 10.1212/WNL.0b013e3181a0fe3f
    1. Martinez MA, Olsson B, Bau L, Matas E, Cobo Calvo A, Andreasson U, et al. . Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. (2015) 21:550–61. 10.1177/1352458514549397
    1. Matute-Blanch C, Villar LM, Alvarez-Cermeno JC, Rejdak K, Evdoshenko E, Makshakov G, et al. . Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. (2018) 141:1085–93. 10.1093/brain/awy021
    1. Hakansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, et al. . Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. (2017) 24:703–12. 10.1111/ene.13274
    1. Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A, et al. . CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. (2013) 19:436–42. 10.1177/1352458512458010
    1. Fialova L, Bartos A, Svarcova J, Zimova D, Kotoucova J, Malbohan I. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol. (2013) 262:113–20. 10.1016/j.jneuroim.2013.06.010
    1. Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, et al. . Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry. (2016) 87:126–9. 10.1136/jnnp-2014-309690
    1. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. (2003) 61:1720–5. 10.1212/01.WNL.0000098880.19793.B6
    1. Varhaug KN, Barro C, Bjornevik K, Myhr KM, Torkildsen O, Wergeland S, et al. . Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. (2018) 5:e422. 10.1212/NXI.0000000000000422
    1. Kuhle J, Malmestrom C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, et al. . Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand. (2013) 128:e33–6. 10.1111/ane.12151
    1. Bhan A, Jacobsen C, Myhr KM, Dalen I, Lode K, Farbu E. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. (2018) 24:1301–7. 10.1177/1352458518782005
    1. Hakansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, et al. . Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J Neuroinflammation. (2018) 15:209. 10.1186/s12974-018-1249-7
    1. Trentini A, Comabella M, Tintore M, Koel-Simmelink MJ, Killestein J, Roos B, et al. . N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. J Neurol. (2014) 261:2338–43. 10.1007/s00415-014-7507-4
    1. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. (2010) 16:287–92. 10.1177/1352458509359725
    1. Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, et al. . Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. (2018). 10.1177/1352458518765666. [Epub ahead of print].
    1. Mellergard J, Tisell A, Blystad I, Gronqvist A, Blennow K, Olsson B, et al. . Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. (2017) 24:112–21. 10.1111/ene.13162
    1. Tortorella C, Direnzo V, Ruggieri M, Zoccolella S, Mastrapasqua M, D'Onghia M, et al. . Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. (2018) 24:1039–45. 10.1177/1352458517711774
    1. Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, et al. . Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. (2011) 69:83–9. 10.1002/ana.22247
    1. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, et al. . Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. (2015) 84:1639–43. 10.1212/WNL.0000000000001491
    1. de Flon P, Gunnarsson M, Laurell K, Soderstrom L, Birgander R, Lindqvist T, et al. . Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. (2016) 87:141–7. 10.1212/WNL.0000000000002832
    1. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmestrom C, et al. . Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem. (2017) 141:296–304. 10.1111/jnc.13881
    1. Axelsson M, Malmestrom C, Gunnarsson M, Zetterberg H, Sundstrom P, Lycke J, et al. . Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. (2014) 20:43–50. 10.1177/1352458513490544
    1. Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat. (2018) 14:2241–54. 10.2147/NDT.S173280
    1. Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. (2019) 90:157–64. 10.1136/jnnp-2018-318704
    1. Weydt P, Oeckl P, Huss A, Muller K, Volk AE, Kuhle J, et al. . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. (2016) 79:152–8. 10.1002/ana.24552
    1. Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobagyi T, Hoglund K, et al. . Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. (2019) 7:5. 10.1186/s40478-018-0649-3
    1. Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. (2016) 87:1329–36. 10.1212/WNL.0000000000003154
    1. Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al. . Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. (2016) 3:216–25. 10.1002/acn3.290
    1. Shahim P, Gren M, Liman V, Andreasson U, Norgren N, Tegner Y, et al. . Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. (2016) 6:36791. 10.1038/srep36791
    1. Wallace C, Zetterberg H, Blennow K, van Donkelaar P. No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. PLoS ONE. (2018) 13:e0206466. 10.1371/journal.pone.0206466
    1. Thompson AGB, Luk C, Heslegrave AJ, Zetterberg H, Mead SH, Collinge J, et al. . Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry. (2018) 89:955–61. 10.1136/jnnp-2017-317793
    1. Novakova L, Axelsson M, Malmestrom C, Imberg H, Elias O, Zetterberg H, et al. . Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers. PLoS ONE. (2018) 13:e0194828. 10.1371/journal.pone.0194828
    1. Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, et al. . Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. (2018) 5:1478–91. 10.1002/acn3.638

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe